Haematologisch Onkologische Schwerpunktpraxis — Clinical Trial Site

18 Registered trials

6 Currently recruiting

Organisation

Haematologisch Onkologische Schwerpunktpraxis

Location

Wuerzburg, Germany

Identifier

ORG-100043152

Address

Schweinfurter Strasse 7, Altstadt, 97080, Germany

Departments

Facharzt für Innere Medizin, Hämatologie und Internistische Onkologie
Gemeinschaftspraxis
Gemeinschaftspraxis Dr. med. rudolf Schlag/ Dr. med. björn Schöttker
Gemeinschaftspraxis Dres. Schöttker & Pretscher
Haematologisch Onkologische Schwerpunktpraxis
Haematology/Onkology
Hämatologie/Onkologie
Hämatologisch-Onkologische Schwerpunktpraxis
Hämatologisch-Onkologische Schwerpunktpraxis Würzburg & Kitzingen
Hematology and Oncology
Hematology-oncology specialist practice
Innere Medizin, Hämatologie und Internistische Onkologie
Internal Medicine, Hematology and Medical Oncology
N/A
NA

Clinical trials at this site (18)

Search interface

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st… Pending

2024-516734-35-00 triple-negative early breast cancer 5
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P… Recruiting

2024-517131-52-00 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small 5 2025-11-03
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Myelodysplastic Syndrome (MDS) 5 2023-10-11
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended

2023-509859-13-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-11-09
A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat… Ended

2023-507698-16-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-10-14
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 4 2021-01-28
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended

2022-500584-12-00 Waldenström’s Macroglobulinemia 4 2019-09-11
This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre… Ended

2023-509349-11-00 Previously untreated Chronic Lymphocytic Leukemia Witho 5 2019-03-22
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended

2022-501485-22-00 Myelodysplastic syndrome (MDS) 5 2018-12-18
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi… Ended

2023-509348-84-00 Chronic Lymphocytic Leukemia 5 2015-04-27
CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended

2023-507002-14-00 treatment-naïve or relapsed/refractory chronic lymphocy 4 2021-05-20